Please try another search
For the three months ended 31 March 2022, KoBioLabs Inc revenues increased 48% to W1.05B. Net loss increased 23% to W3.65B. Revenues reflect Probiotics(ODM) segment increase from W0K to W115.5M, Probiotics segment increase of 6% to W755M. Higher net loss reflects R & D Expense increase of 42% to W3.22B (expense), Interest Expense increase from W3.4M to W371M (expense).
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 10586.69 | 7703.4 | 7150.74 | 7697.21 |
Gross Profit | 7626.53 | 5543.31 | 4916.4 | 5622.35 |
Operating Income | -6048.97 | -3741.9 | -4503.08 | -4164.1 |
Net Income | -5523.54 | -3230.07 | -1637.51 | -3461.63 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 114622.91 | 117655.83 | 120768.84 | 121782.6 |
Total Liabilities | 52803.92 | 32997.26 | 32569.04 | 29730.22 |
Total Equity | 61818.99 | 84658.57 | 88199.8 | 92052.38 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -5052.5 | -2542.56 | -3869.98 | -2367.32 |
Cash From Investing Activities | 3668.2 | 4547.9 | -1274.43 | 1250.45 |
Cash From Financing Activities | 1945.74 | 846.05 | 1351.68 | -97.33 |
Net Change in Cash | 1649.31 | 2833.89 | -3883.32 | -986.12 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review